Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Breathe (Sheffield, England)
|
July 23, 2021
The patient perspective of alpha-1 antitrypsin deficiency: disease burden and unmet needs
Marion Wilkens, Michael Bartlett, Frank Willersinn, et al.
ERJ Open Research
|
January 15, 2021
Research priorities in α<sub>1</sub>-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
Miriam Barrecheguren, Karen O'Hara, Marion Wilkens, et al.
The Oncologist
|
July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Cristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
European Urology
|
February 25, 2022
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
Sumanta K Pal, Javier Puente, Daniel Y C Heng, et al.
Cancer
|
October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.
European Urology
|
October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Pediatric Blood & Cancer
|
May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Filemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
ERJ Open Research
|
March 11, 2020
Protocol for the EARCO Registry: a pan-European observational study in patients with α<sub>1</sub>-antitrypsin deficiency
Timm Greulich, Alan Altraja, Miriam Barrecheguren, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Breathe (Sheffield, England)
|
July 23, 2021
The patient perspective of alpha-1 antitrypsin deficiency: disease burden and unmet needs
Marion Wilkens, Michael Bartlett, Frank Willersinn, et al.
ERJ Open Research
|
January 15, 2021
Research priorities in α<sub>1</sub>-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
Miriam Barrecheguren, Karen O'Hara, Marion Wilkens, et al.
The Oncologist
|
July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Cristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
European Urology
|
February 25, 2022
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
Sumanta K Pal, Javier Puente, Daniel Y C Heng, et al.
Cancer
|
October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.
European Urology
|
October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Pediatric Blood & Cancer
|
May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Filemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
ERJ Open Research
|
March 11, 2020
Protocol for the EARCO Registry: a pan-European observational study in patients with α<sub>1</sub>-antitrypsin deficiency
Timm Greulich, Alan Altraja, Miriam Barrecheguren, et al.
Page
of 1